BEAM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BEAM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Beam Therapeutics's Net Income for the three months ended in Mar. 2024 was $-98.7 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-134.7 Mil.
Net Income is linked to the most popular Earnings per Share (Diluted) number. Beam Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.21.
The historical data trend for Beam Therapeutics's Net Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Net Income | Get a 7-Day Free Trial | -78.33 | -194.59 | -370.64 | -289.09 | -132.53 |
Beam Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net Income | Get a 7-Day Free Trial | -96.46 | -82.78 | -96.09 | 142.80 | -98.67 |
Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.
Net Income
= Revenue
- Cost of Goods Sold
- Selling, General, & Admin. Expense
- Research & Development
- Depreciation, Depletion and Amortization
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= EBITDA
- Depreciation, Depletion and Amortization
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= Operating Income
- Interest Expense
- Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others
Beam Therapeutics's Net Income for the fiscal year that ended in Dec. 2023 is calculated as
Net Income | (A: Dec. 2023 ) | ||||||
= | Pre-Tax Income | + | Tax Provision | + | Net Income (Discontinued Operations) | + | Others |
= | -131.161 | + | -1.366 | + | 0 | + | 2.8421709430404E-14 |
= | -132.5 |
Beam Therapeutics's Net Income for the quarter that ended in Mar. 2024 is calculated as
Net Income | (Q: Mar. 2024 ) | ||||||
= | Pre-Tax Income | + | Tax Provision | + | Net Income (Discontinued Operations) | + | Others |
= | -98.669 | + | 0 | + | 0 | + | 0 |
= | -98.7 |
Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-134.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (NAS:BEAM) Net Income Explanation
Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:
Beam Therapeutics's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as
Earnings per Share (Diluted) (Q: Mar. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-98.669 | - | 0) | / | 81.699 | |
= | -1.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
EPS is most useful for companies that have:
A predictable businessThe dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Beam Therapeutics's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Christine Bellon | officer: Chief Legal Officer | BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142 |
Amy Simon | officer: Chief Medical Officer | BEAM THERAPEUTICS, INC., 238 MAIN STREET, 9TH FL., CAMBRIDGE MA 02142 |
Giuseppe Ciaramella | officer: President & CSO | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
John M. Evans | director, officer: CEO | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Terry-ann Burrell | officer: CFO | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Fmr Llc | 10 percent owner, other: See Remark 1 | 245 SUMMER STREET, BOSTON MA 02210 |
John Maraganore | director | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Graham K Cooper | director | C/O RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Kathleen E Walsh | director | C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001 |
Arch Venture Fund Ix Overage, L.p. | 10 percent owner | 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631 |
Stephen C Knight | director | C/O EPIX MEDICAL INC, 71 ROGERS ST, CAMBRIDGE MA 02142 |
Mark Fishman | director | C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Arch Venture Partners Ix, Llc | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Ix, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Arch Venture Partners Ix Overage, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By PRNewswire • 12-11-2023
By Business Wire Business Wire • 08-03-2022
By sperokesalga sperokesalga • 02-28-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 11-03-2022
By Stock market mentor Stock market mentor • 02-07-2023
By Ds*** Ds*** • 09-01-2022
By Marketwired • 09-05-2023
By Marketwired • 08-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.